On June 5, China Biopharmaceuticals announced that the company announced the results of a Phase III clinical study on non-small cell lung cancer at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting. The study showed that the median progression-free survival (PFS) of the treatment group using bemosubishi combined with anlotinib was significantly extended to 15.1 months, while the control group was only 4.2 months, and the risk of disease progression or death was reduced by 51%. A total of 553 patients were included in this study, including 209 patients in trial group 1, 212 patients in trial group 2, and 132 patients in the control group.

Preliminary results showed that the median PFS of trial group 1 was extended by 10.9 months compared with the control group, and trial group 2 was also significantly extended by 5.5 months. In terms of safety, the incidence of grade ≥3 treatment-related adverse events was 48.8%, 29.4%, and 19.7%, respectively. The breakthrough results of this study may reshape clinical practice guidelines and benefit more patients with non-small cell lung cancer. In addition, based on the results of this study, the new indication application for bemosubishizumab with or without anlotinib was accepted by the Drug Review Center of the China National Drug Administration in April 2025.

https://finance.eastmoney.com/a/202506053422846883.html